Dishman Carbogen Amcis Stock Screener | Share Price & Fundamental Analysis
DCAL
Pharmaceuticals
Share Price NSE
₹182.28
▼
-7.88 (-4.14%)
Share Price BSE
₹182.45
▼
-7.70 (-4.05%)
Track Dishman Carbogen Amcis share price live with TickJournal's free stock screener.
Analyze Dishman Carbogen Amcis share price history trends and compare 52-week high low
levels.
Calculate DCAL stock fair value using fundamental analysis and view live share price charts.
Determine Dishman Carbogen Amcis share intrinsic value and compare it with current DCAL share price.
Record your Dishman Carbogen Amcis trades in TickJournal's free trading journal and track your portfolio performance.
Dishman Carbogen Amcis Market Cap
₹3,082.20 Cr.
DCAL P/E Ratio (TTM)
26.63
EPS (TTM)
₹0.21
Dividend Yield
-
Debt to Equity
0.41
DCAL 52 Week High
₹314.00
Dishman Carbogen Amcis 52 Week Low
₹182.28
Operating Margin
20.00%
Profit Margin
5.94%
DCAL Revenue (TTM)
₹724.00
EBITDA
₹149.00
Net Income
₹43.00
Total Assets
₹9,999.00
Total Equity
₹5,832.00
Dishman Carbogen Amcis Share Price History - Stock Screener Chart
Screen DCAL historical share price movements with interactive charts. Analyze price trends and patterns.
Dishman Carbogen Amcis Company Profile - Fundamental Screener
Screen Dishman Carbogen Amcis company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics
for DCAL shares.
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
ISIN
INE385W01011
Dishman Carbogen Amcis Balance Sheet Screener
Screen DCAL balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation
metrics.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||
| Total Assets | 9,999 | 9,581 | 9,454 | 8,638 | 8,366 | 8,200 | 7,329 | 7,177 | 6,593 |
| Current Assets | 2,200 | 1,928 | 1,918 | 1,839 | 1,704 | 1,779 | 1,554 | 1,546 | 1,245 |
| Fixed Assets | 7,055 | 6,724 | 6,188 | 5,773 | 5,698 | 5,678 | 5,098 | 5,066 | 4,852 |
| Liabilities | |||||||||
| Total Liabilities | 9,999 | 9,581 | 9,454 | 8,638 | 8,366 | 8,200 | 7,329 | 7,177 | 6,593 |
| Current Liabilities | 2,243 | 1,399 | 1,845 | 1,669 | 1,377 | 916 | 751 | 891 | 786 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | |||||||||
| Total Equity | 5,832 | 5,628 | 5,810 | 5,549 | 5,699 | 5,715 | 5,379 | 5,107 | 4,814 |
| Share Capital | 31 | 31 | 31 | 31 | 31 | 31 | 32 | 32 | 0 |
| Reserves & Surplus | 5,800 | 5,596 | 5,778 | 5,518 | 5,668 | 5,684 | 5,347 | 5,075 | 4,814 |
Dishman Carbogen Amcis Income Statement Screener - Profit & Revenue Analysis
Screen Dishman Carbogen Amcis income statement and profit fundamentals.
Analyze DCAL quarterly results,
revenue growth, EBITDA, net profit margins, and EPS using TickJournal's fundamental screener for Dishman Carbogen Amcis share price evaluation.
| Item | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec | 2023-Mar | 2023-Jun | 2023-Sept | 2023-Dec | 2022-Mar | 2022-Jun | 2022-Sept |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 724 | 733 | 661 | 727 | 662 | 525 | 796 | 690 | 625 | 730 | 595 | 657 | 573 | 546 | 623 |
| Expenses | 575 | 570 | 504 | 607 | 595 | 500 | 645 | 542 | 613 | 602 | 529 | 610 | 559 | 452 | 535 |
| EBITDA | 149 | 163 | 157 | 120 | 67 | 25 | 151 | 148 | 13 | 128 | 66 | 47 | 14 | 94 | 88 |
| Operating Profit % | 20.00% | 19.00% | 23.00% | 16.00% | 9.00% | 4.00% | 18.00% | 21.00% | 1.00% | 17.00% | 10.00% | 6.00% | 2.00% | 16.00% | 13.00% |
| Depreciation | 79 | 81 | 84 | 84 | 85 | 71 | 72 | 72 | 76 | 70 | 75 | 80 | 84 | 75 | 80 |
| Interest | 42 | 43 | 42 | 46 | 31 | 32 | 37 | 49 | 24 | 29 | 28 | 33 | 16 | 19 | 20 |
| Profit Before Tax | 28 | 39 | 31 | -10 | -49 | -78 | 42 | 27 | -88 | 30 | -36 | -66 | -85 | 0 | -12 |
| Tax | -15 | 15 | -35 | 3 | 21 | 0 | 9 | 22 | -17 | 13 | 5 | -7 | -41 | -4 | -2 |
| Net Profit | 43 | 23 | 65 | -13 | -70 | -78 | 33 | 5 | -71 | 17 | -41 | -60 | -45 | 4 | -10 |
| EPS | 2.75 | 1.49 | 4.16 | -0.83 | -4.46 | -4.95 | 2.11 | 0.30 | -4.51 | 1.08 | -2.61 | -3.80 | -2.85 | 0.26 | -0.64 |
Dishman Carbogen Amcis Cash Flow Screener - Liquidity Fundamentals
Screen DCAL cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price
strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2012-March |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | 375 | 379 | 266 | 355 | 513 | 585 | 282 | 226 | 303 | 154 |
| Investing Activities | -196 | -225 | -494 | -619 | -380 | -442 | -169 | -297 | -107 | -104 |
| Financing Activities | -102 | -22 | 250 | 130 | -11 | -98 | -102 | 78 | -137 | -68 |
| Net Cash Flow | 77 | 132 | 22 | -133 | 122 | 46 | 11 | 7 | 59 | -19 |
Dishman Carbogen Amcis Shareholding Pattern Screener
See Dishman Carbogen Amcis shareholding pattern with promoter, FII, and DII holdings.
Check Dishman Carbogen Amcis promoter holding and ownership changes for DCAL on TickJournal.
| Item | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 59.32% | 59.32% | 59.32% | 59.32% | 59.32% | 59.32% | 59.32% | 59.32% |
| FII Holding | 9.49% | 9.93% | 8.07% | 7.66% | 8.70% | 8.04% | 8.17% | 8.74% |
| DII Holding | 1.26% | 1.27% | 1.37% | 1.27% | 2.37% | 1.48% | 1.23% | 1.42% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 25.31% | 25.36% | 26.84% | 27.31% | 25.17% | 27.10% | 27.43% | 26.22% |
| Other Holding | 4.62% | 4.11% | 4.39% | 4.44% | 4.45% | 4.06% | 3.85% | 4.29% |
| Shareholder Count | 50,757 | 49,744 | 49,455 | 48,481 | 50,656 | 53,683 | 55,280 | 52,822 |
Dishman Carbogen Amcis Share Dividend Screener - Share Yield Analysis
Check Dishman Carbogen Amcis dividend history with payout and yield data.
View Dishman Carbogen Amcis dividend details including ex-dates and amounts for DCAL stock.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹0.00 | 0.00% |
| 2025-March | ₹0.00 | 0.00% |
| 2024-March | ₹0.00 | 0.00% |
| 2023-March | ₹0.00 | 0.00% |
| 2022-March | ₹0.00 | 0.00% |
| 2021-March | ₹0.00 | 0.00% |
| 2020-March | ₹0.00 | 0.00% |
| 2019-March | ₹0.20 | 0.37% |
| 2018-March | ₹0.00 | 0.00% |
| 2017-March | ₹1.20 | 0.37% |
Dishman Carbogen Amcis Stock Index Membership
See which indices include Dishman Carbogen Amcis stock.
Check DCAL index membership in NIFTY 50, SENSEX, and other indices on TickJournal.
Dishman Carbogen Amcis Market Events Screener - Corporate Actions
Get Dishman Carbogen Amcis corporate actions including splits, bonuses, and buybacks.
Check Dishman Carbogen Amcis stock events that may affect DCAL share price.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| Annual General Meeting | NA | -4.79% | ||
| Annual General Meeting | NA | 4.48% | ||
| 2026-02-03 | 2026-02-03 | Quarterly Result Announcement | NA | 5.52% |
| 2025-11-04 | 2025-11-04 | Quarterly Result Announcement | NA | -0.26% |
| 2025-08-12 | 2025-08-12 | Quarterly Result Announcement | NA | -0.79% |
| 2025-05-21 | 2025-05-21 | Quarterly Result Announcement | NA | 0.97% |
| 2025-02-12 | 2025-02-12 | Quarterly Result Announcement | NA | -5.73% |
| 2024-11-13 | 2024-11-13 | Quarterly Result Announcement | NA | -2.51% |
| 2017-03-27 | 2017-03-27 | Change Of Name | NA | - |
Dishman Carbogen Amcis Competitors Screener - Peer Comparison
Screen DCAL competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better
stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 408,007 | 37.20 | 54,729 | 9.71% | 10,980 | 53.25 |
| Divis Laboratories | 163,250 | 66.07 | 9,712 | 18.67% | 2,191 | 48.15 |
| Torrent Pharmaceuticals | 144,229 | 64.43 | 11,539 | 6.99% | 1,911 | 70.35 |
| Cipla | 109,566 | 23.71 | 28,410 | 7.12% | 5,291 | 45.95 |
| Dr Reddys Laboratories | 105,948 | 19.16 | 33,741 | 16.73% | 5,725 | 58.53 |
| Lupin | 101,478 | 21.52 | 22,910 | 13.74% | 3,306 | 60.82 |
| Zydus Life Science | 91,613 | 18.12 | 23,511 | 18.55% | 4,615 | 52.96 |
| Mankind Pharma | 86,000 | 47.17 | 12,744 | 20.90% | 2,007 | 45.43 |
| Aurobindo Pharma | 68,802 | 19.14 | 32,346 | 9.43% | 3,484 | 51.95 |
| Alkem Laboratories | 65,528 | 26.80 | 13,458 | 3.70% | 2,216 | 40.44 |
Dishman Carbogen Amcis Company Announcements - News Screener
Screen DCAL latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2026-02-15 | Announcement under Regulation 30 (LODR)-Earnings Call Transcript | View |
| 2026-02-04 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | View |
| 2026-02-04 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | View |
| 2026-02-04 | Announcement under Regulation 30 (LODR)-Investor Presentation | View |
| 2026-02-03 | Board Meeting Outcome for UN-AUDITED FINANCIAL RESULTS AND STATUTORY AUDITORS LIMITED REVIEW REPORT FOR THE THIRD QUARTER ENDED 31/12/2025 | View |
| 2026-02-03 | UN-AUDITED FINANCIAL RESULTS AND STATUTORY AUDITORS LIMITED REVIEW REPORT FOR THE THIRD QUARTER ENDED 31/12/2025 | View |
| 2026-01-30 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | View |
| 2026-01-29 | Board Meeting Intimation for Considering Take On Record And Approve The Un-Audited Financial Results Of The Company For The Third Quarter Ended On 31St December 2025 | View |
| 2026-01-20 | Announcement under Regulation 30 (LODR)-Allotment | View |
| 2026-01-12 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | View |
| 2026-01-06 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | View |
| 2025-12-27 | Board Meeting Outcome for BOARD MEETING OUTCOME FOR BOARD APPROVES ISSUE OF SENIOR SECURED RATED LISTED TRANSFERABLE TAXABLE REDEEMABLE NON-CONVERTIBLE DEBENTURES AGGREGATING UP TO RS. 50 CRORES | View |
| 2025-12-23 | Closure of Trading Window | View |
| 2025-12-23 | Board Meeting Intimation for Considering And Approving The Proposal Of Fund Raising By Way Of Issuance Of Non-Convertible Debentures By Way Of Private Placement Subject To Such Regulatory Or Statutory Approvals As May Be Required | View |
| 2025-12-20 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | View |
| 2025-11-12 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | View |
| 2025-11-11 | Announcement under Regulation 30 (LODR)-Earnings Call Transcript | View |
| 2025-11-05 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | View |
| 2025-11-05 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | View |
| 2025-11-05 | Announcement under Regulation 30 (LODR)-Investor Presentation | View |